江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-009 江苏森萱医药股份有限公司 第四届监事会第八次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 13 日 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼会议 室 3.会议召开方式：以现场加通讯方式召开 5.会议主持人：秦建 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 监事封乃军因出差以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2024 年度监事会工作报告>的议案》 1.议案内容： 公司监事会主席秦建先生代表监事会，对公司监事会 2024 年度主要工作及 4.发出监事会会议通知的时间和方式：2025 年 3 月 31 日 以书面、 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-008 江苏森萱医药股份有限公司 第四届董事会第八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 13 日 2.会议召开地点：江苏省南通市崇川区青年中路 198 号国城广场 A 幢 21 楼 会议室 3.会议召开方式：以现场加通讯方式召开 4.发出董事会会议通知的时间和方式：2025 年 3 月 31 日以书面、邮件方式 发出 5.会议主持人：吴玉祥 6.会议列席人员：公司监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事沈小燕因出差以通讯方式参与表决。 1.议案内容： 根据公司 2024 年实际经营情况，公司总经理袁拥军先生代表公司经营层， 对公司 2024 年度经营 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-022 江苏森萱医药股份有限公司 2024 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏森萱医药股份有限公司（以下简称"公司"）为积极回报股东、与全体股 东分享公司经营成果，在综合考虑公司战略规划、现金流量情况，保证公司健康、 稳定、持续发展的前提下，根据相关法律法规及《公司章程》、《利润分配管理制 度》、《2023 年至 2025 年三年分红回报规划》等要求，公司拟实施 2024 年年度 利润分配，具体如下： 一、权益分派预案情况 根据公司 2025 年 4 月 14 日披露的 2024 年年度报告（财务报告已经审计）， 截至 2024 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 496,377,191.59 元，母公司未分配利润为 67,887,867.13 元。 公司本次权益分派预案如下：公司目前总股本为 426,918,340 股，以未分配 利润向全体 ...

Financial Performance - In 2024, Jiangsu Senxuan Pharmaceutical reported a revenue of ¥537,136,066.43, a decrease of 8.89% compared to ¥589,560,024.01 in 2023[27] - The net profit attributable to shareholders was ¥123,759,884.41, down 8.00% from ¥134,523,788.78 in the previous year[27] - Basic earnings per share decreased to ¥0.2899, down 8.00% from ¥0.3151 in 2023[27] - Operating cash flow decreased by 9.59% to ¥171,257,287.81 compared to 2023[28] - The company achieved operating revenue of 537.14 million yuan, a decrease of 8.89% year-on-year, and a net profit attributable to shareholders of 123.76 million yuan, down 8.00% year-on-year[44] - The net cash flow from operating activities for 2024 was ¥171,257,287.81, a decrease of 9.59% compared to ¥189,413,303.80 in 2023[67] - The total investment amount for the reporting period was ¥165,000,000.00, down 30.67% from ¥238,000,000.00 in the previous year[70] Profitability and Margins - The gross profit margin improved to 43.58% in 2024 from 43.01% in 2023[27] - The interest coverage ratio improved to 253.21 from 175.45 in 2023[28] - The weighted average return on equity based on net profit attributable to shareholders was 10.69% in 2024, down from 12.18% in 2023[27] - Non-recurring gains and losses totaled ¥7,444,388.62 for 2024[35] Assets and Liabilities - Total assets increased by 2.02% to ¥1,354,157,745.02 compared to the end of 2023[28] - Total liabilities decreased by 24.20% to ¥89,240,145.11 compared to the end of 2023[28] - Net assets attributable to shareholders increased by 4.87% to ¥1,191,365,157.56 compared to the end of 2023[28] Market and Product Development - The company plans to continue expanding its product offerings and market presence in the pharmaceutical sector[12] - The company is advancing the construction of a project with an annual output of 40 tons of Lopinavir and 60 tons of Ritonavir, which is expected to contribute to future revenue growth[44] - The company is developing new products and expanding its market through various R&D projects, including those in the small trial stage[86] - The company aims to launch 1-2 new raw material drug varieties annually, stabilizing the proportion of raw material drug sales in total revenue[137] Research and Development - R&D expenditure amounted to ¥28,636,950.09, representing 5.33% of operating revenue, an increase from 4.78% in the previous period[82] - The total number of R&D personnel decreased from 108 to 91, with the proportion of R&D staff to total employees rising from 15.19% to 16.77%[83] - The company holds a total of 192 patents, up from 150 in the previous period, including 42 invention patents, an increase from 31[84] - The company has successfully optimized the synthesis process for Ritonavir, achieving a total yield of 40-50% and a compound purity exceeding 99%[92] Environmental Compliance - The company complied with environmental protection standards and regulations, ensuring proper waste management and emissions control[99] - The environmental protection licenses for various projects were obtained, with validity extending until 2029 for some projects[101] - The company conducts annual monitoring of volatile organic compounds (VOCs) and other pollutants at the waste gas incineration furnace, with specific monitoring frequencies for various substances[110] - The company has implemented online monitoring devices for wastewater discharge, ensuring real-time data transmission to local environmental authorities[116] Corporate Governance and Compliance - The company identified revenue recognition as a key audit matter due to the inherent risk of management manipulating revenue to meet specific targets[93] - The audit response included analytical review of revenue, testing of internal controls, and sampling of domestic and international sales transactions[93] - The company’s audit committee confirmed that the accounting firm has no relationships affecting its independence and has experience in auditing listed companies[96] Employee Management - The total number of employees decreased from 644 to 599 during the reporting period, with a reduction of 59 employees[188] - The company maintains a stable employee compensation policy that includes fixed salaries and performance-based incentives[189] - The company has established training programs in collaboration with renowned universities to enhance employee skills[189] Risks and Challenges - The company faces environmental regulatory risks due to stricter pollution control measures, which may increase production costs and lead to the elimination of non-compliant enterprises[138] - The company is exposed to tax policy risks related to high-tech enterprise status, which could impact operations if tax incentives are lost[139] - The company is at risk of foreign exchange losses due to RMB fluctuations as it expands its overseas market presence, which may affect product pricing and competitiveness[139] Community Engagement - The company actively responded to national poverty alleviation policies through donations and support for remote areas[97]

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 33144.64万股，累计占流通股比： 77.66%，较上期变化： -710.77万股。 一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况 | | --- | --- | --- | --- | | | | (%) | (万股) | | 精华制药（002349）集团股份有限公司 | 30872.43 | 72.34 | 不变 | | 童贞明 | 1366.56 | 3.20 | -573.21 | | 林良墩 | 281.82 | 0.66 | 98.59 | | 北京银行股份有限公司-创金合信北证50成份指数增强型 证券投资基金 | 138.25 | 0.32 | 新进 | | 丁海峰 | | | | | 107.43 | | 0.25 | -1.17 | | 贾红声 | 85.03 | 0.20 | 新进 | | 国信证券股份有限公司-西藏东财北证50成份指数型发起 式证券投资基金 | 83.67 | 0.20 | 新进 | | 北京银行股份有限公司-工银瑞信北证50 ...

Financial Performance - The company reported a total revenue of ¥537,136,066.43 for the reporting period, representing a decrease of 8.89% compared to the previous year[3] - The net profit attributable to shareholders was ¥122,775,968.62, down 8.73% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥115,738,710.97, reflecting a decline of 9.66% compared to the same period last year[3] - Basic earnings per share decreased to ¥0.2876, down 8.73% from the previous year[3] Assets and Equity - Total assets at the end of the reporting period were ¥1,352,068,923.10, an increase of 1.87% year-on-year[3] - Shareholders' equity attributable to the company increased by 4.79% to ¥1,190,381,241.77[3] Market Factors - The decline in revenue and profit was primarily due to price drops in anti-tumor raw materials influenced by centralized procurement[5] Product Development - The company launched two new raw materials, Letermovir and Indocyanine Green, which generated commercial orders during the reporting period[5] Strategic Focus - The company focused on internal optimization, cost reduction, and enhancing product competitiveness to stabilize revenue and gross profit[5] Financial Caution - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[6]

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-004 江苏森萱医药股份有限公司 投资者关系活动记录表 活动时间：2025 年 2 月 13 日 活动地点：上海市浦东新区富城路 33 号香格里拉大酒店 参会单位及人员：开源证券、国泰君安、东北证券、北京明德蓝鹰投资、厦 门国贸投资、乾和资产、冲积资产。 上市公司接待人员：董事会秘书、财务总监朱狮章先生 三、 投资者关系活动主要内容 问题 1：公司在创新方面有哪些方式和途径？ 回答：您好，公司的创新方式和途径主要有以下几点：管理上成立了知识 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 √特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 回答：您好，中间体主要是公司为原料药产业链配套，解决原料供应的安 全性，公司也会对外销售，但主要是提升原料药的竞争力，二者相互促进、相 辅相成，未做具体比例安排，最终目的是提升原 ...

Investment Rating - The investment rating for the company is "Hold (First Coverage)" [1] Core Views - The company focuses on the production of active pharmaceutical ingredients (APIs) and intermediates, aiming to become a leading domestic and globally recognized manufacturer in this field. It has a clear strategy to diversify into innovative and generic drugs while maintaining a strong position in the API market [4][25][39] - The company has a stable customer base, with the top five customers accounting for 27.27% of sales in 2023, indicating strong customer relationships and stable sales channels [40][44] - The company has faced financial pressures in recent years, with a decline in revenue and net profit, but the decline in net profit has narrowed as of Q3 2024, showing signs of stabilization [7][43] Summary by Sections Company Overview - Jiangsu Senxuan Pharmaceutical Co., Ltd. was established in 2003 and is one of the first companies listed on the Beijing Stock Exchange. The company has a clear ownership structure with state-owned assets controlling 72.31% of shares, providing strategic guidance and support for sustainable development [11][22] - The company has received various recognitions, including "Specialized, Refined, Characteristic, and Innovative" and "High-tech Enterprise" certifications, which enhance its market competitiveness [17] Financial Forecast - The company's total revenue is projected to be 533.55 million yuan in 2024, with a growth rate of -9.50%, followed by 622.44 million yuan in 2025 and 718.17 million yuan in 2026, with growth rates of 16.66% and 15.38% respectively [5] - The net profit attributable to shareholders is expected to be 123.23 million yuan in 2024, with a decline of 8.39%, followed by 135.39 million yuan in 2025 and 159.25 million yuan in 2026, with growth rates of 9.87% and 17.62% respectively [5] Industry Development - The global pharmaceutical industry is experiencing continuous growth, driven by population growth and aging trends, which presents opportunities for companies in this sector [2][16] - The company is positioned to benefit from the expiration of patents for original drugs and the acceleration of domestic approvals, allowing it to deepen its product development and optimize its product structure [29][30] Valuation and Investment Recommendations - The current market valuation corresponds to a price-to-earnings (P/E) ratio of 32.53 for 2024, 29.61 for 2025, and 25.17 for 2026, indicating a favorable outlook for future earnings growth [5][7]

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-002 江苏森萱医药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 1 月 16 日 3.会议召开方式：现场投票和网络投票相结合 4.会议召集人：董事会 5.会议主持人：吴玉祥 6.召开情况合法、合规、合章程性说明： 本次股东大会的召开符合《公司法》等有关法律、法规及《公司章程》的规 定。 （二）会议出席情况 出席和授权出席本次股东大会的股东共 5 人，持有表决权的股份总数 322,464,401 股，占公司有表决权股份总数的 75.533040%。 其中通过网络投票参与本次股东大会的股东共 2 人，持有表决权的股份总数 13,565,061 股，占公司有表决权股份总数的 3.177437%。 2.会议召开地点：南通市崇川区观音山街道青年中路 198 号国城生活广场 A 幢 21 楼会议 ...

2025年第一次临时股东大会法律意见书 森菅医药 江苏世纪同仁律师事务所 关于江苏森萱医药股份有限公司 2025 年第一次临时股东大会的法律意见书 江苏森萱医药股份有限公司: 1、本次股东大会由贵公司董事会召集。 贵公司第四届董事会第七次会议决定于 2025年 1 月 16 日召开本次股东大 会。贵公司已于 2024年 12月 30 目在北京证券交易所信息披露平台(www.bse.cn) 上刊登了《江苏森萱医药股份有限公司关于召开 2025 年第一次临时股东大会的 通知》。 贵公司在法定期限内公告了本次股东大会的时间、地点、会议议程、出席对 象及出席会议登记办法、临时通知的发出等相关事项,符合《公司章程》的规定。 根据《公司法》《证券法》和中国证监会《上市公司股东大会规则》等法律、 法规和规范性文件以及《公司章程》的规定,本所受贵公司董事会的委托,指派 本所律师出席贵公司 2025年第一次临时股东大会,并就本次股东大会的召集、 召开程序、出席会议人员资格、召集人资格、表决程序和表决结果的合法有效性 出具法律意见。 为出具本法律意见书,本律师对本次股东大会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有 ...